ONWARD Medical
Develops therapies for spinal cord injury aimed at restoring neurological function and mobility for people affected by paralysis.
Overview
ONWARD Medical develops therapies to treat spinal cord injury, seeking to restore neural function and mobility for patients with paralysis. The company focuses on translating biomedical research into therapeutic programs for patients, clinicians, and healthcare systems managing severe neurological trauma. Headquartered in Eindhoven, Netherlands, ONWARD announced a €40.6 million capital increase on 2026-04-17, reported as $41M total funding across a single disclosed round. The financing is intended to advance its spinal cord injury therapy programs and support progression toward development and commercial objectives.
Funding History
Eindhoven’s ONWARD Medical raises €40.6 million in capital increase to advance spinal cord injury therapies
Frequently Asked Questions
- How much has ONWARD Medical raised in total?
- ONWARD Medical has raised a total of $41M across 1 funding round.
- Who are ONWARD Medical's investors?
- ONWARD Medical's investors include Undisclosed.
- What does ONWARD Medical do?
- ONWARD Medical develops therapies to treat spinal cord injury, seeking to restore neural function and mobility for patients with paralysis. The company focuses on translating biomedical research into therapeutic programs for patients, clinicians, and healthcare systems managing severe neurological trauma. Headquartered in Eindhoven, Netherlands, ONWARD announced a €40.6 million capital increase on 2026-04-17, reported as $41M total funding across a single disclosed round. The financing is intended to advance its spinal cord injury therapy programs and support progression toward development and commercial objectives.
- Where is ONWARD Medical headquartered?
- ONWARD Medical is headquartered in Eindhoven, Netherlands.
Investors
Related Insights
Compare the leading AI-focused VC firms: Andreessen Horowitz, Sequoia Capital, Thrive Capital, and 7 more. Analysis of 150+ AI deals, investment strategies, sector focus, and portfolio performance.
AI startup funding reached $337B across 395 deals in 2026. Complete breakdown of funding stages from pre-seed ($50K-$500K) through IPO, covering valuations, timelines, investor expectations, and how AI funding differs from traditional tech.
An in-depth look at how AI-focused venture capital operates — from fund structure and deal sourcing to due diligence, portfolio management, and exit strategies in the AI era.